http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-353657-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcbc1de8801460caf80ad76627ae20b0 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-15 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-15 |
filingDate | 1968-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 1969-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | ES-353657-A1 |
titleOfInvention | PROCEDURE FOR THE PREPARATION OF 2,6-DIMENTOXIFENYL 2-MORPHOLINOPROPIONATE. |
abstract | Novel 2,6-dimethoxyphenyl 2-morpholinopropionate in the form of the racemate or an optically active isomer, and non-toxic acid addition salts thereof is prepared by:- (a) reacting a compound of the Formula III: where X is the acid residue of a reactive ester with morpholine. or (b) reacting a compound of the Formula IV where Z is hydrogen or an alkali metal atom: with a compound of the Formula VII: where X 1 is a halogen atom or (c) reacting 2,6-dimethoxyphenyl 2-aminopropionate with a compound of the formula X-(CH 2 ) 2 -O-(CH 2 ) 2 -X, where X is as defined above, in the presence of concentrated sulphuric acid. Enantiomorphic forms may be obtained by resolution of the racemate, or use of optically active starting materials. ( - )-[alpha]-Bromopropionyl chloride is obtained by treating the corresponding acid with thionyl chloride and phosphorus trichloride. ( ) - 2,6 - Dimethoxyphenyl 2 - bromopropionate is obtained by adding ( )-[alpha]-bromopropionyl bromide in anhydrous benzene to a solution of 2,6-dimethoxyphenol and anhydrous pyridine in anhydrous benzene and then refluxing. (-) - 2,6 - Dimethoxyphenyl 2 - bromcpropionate is prepared similarly, but using ( - )- [alpha]-bromopropionyl chloride. Pharmaceutical compositions having local anaesthetic activity and containing 2,6-dimethoxyphenyl 2-morpholinopropionate and non- toxic acid addition salts thereof are administered parenterally in association with a pharmaceutical carrier. These compositions may also contain adjuvants such as preserving, wetting, emulsifying, dispersing and solubilizing agents. They may be sterilized, e.g. by filtration through a bacteria-retaining filter, by incorporation of sterilizing agents in the composition or by irradiation. |
priorityDate | 1967-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.